A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

NCT02492763 on ClinicalTrials.gov · last registry update 2018-09-10

Stopped early, having planned 176 participants. The sponsor logged completion for 18 April 2017. Primary outcome, as filed: Change From Baseline in Hemoglobin A1C (A1C) at Week 12. liraglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: TERMINATED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Merck Sharp & Dohme LLC
Sponsor type: Industry
Enrollment: 176
Started: 2015-07-27
Primary completion: 2017-04-18 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Hemoglobin A1C (A1C) at Week 12

Conditions studied

Type II Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.